6505--Carbidopa/Levodopa SA Tablet
ID: 36E79725R0008Type: Solicitation
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OFNAC PHARMACEUTICALS (36E797)HINES, IL, 60141, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/99fd2706b5bf47cdbf7ab1a2002c03a7/view
Timeline
  1. 1
    Posted Jan 16, 2025, 12:00 AM UTC
  2. 2
    Updated Jan 16, 2025, 12:00 AM UTC
  3. 3
    Due Jan 30, 2025, 8:30 PM UTC
Description

The Department of Veterans Affairs is seeking pharmaceutical suppliers to establish a national contract for the provision of Carbidopa/Levodopa SA tablets through its Pharmaceutical Prime Vendor program. The Request for Proposal (RFP) outlines specific requirements for potential contractors, including pricing structures for the base year and four option years, compliance with the Drug Supply Chain Security Act, and the necessity for Good Manufacturing Practices (cGMP) status. This procurement is crucial for ensuring a reliable supply of essential medications for veteran and military healthcare systems across the nation. Interested parties should contact Contract Specialist Christopher Carthron at Christopher.Carthron@va.gov for further details regarding the proposal submission process and deadlines.

Point(s) of Contact
Christopher CarthronContract Specialist
Christopher.Carthron@va.gov
Files
Title
Posted
36E79725R0008_1.docx
Dec 12, 2024, 10:06 PM UTC
The Department of Veterans Affairs (VA) plans to issue Request for Proposal (RFP) 36E79725R0008 for Carbidopa/Levodopa sustained release (SA) tablets, indicating an unrestricted procurement to supply various federal health services, including the Department of Defense and the Bureau of Prisons. The awarded contract will ensure a continuous supply of these medications for one year, with the possibility of extending for four additional yearly periods. Offerors must provide unique branding and packaging without overlapping labels. The electronic solicitation is expected to be issued around January 3, 2026, with offers due by January 17, 2026. Estimated annual usage totals approximately 119,875 bottles split between two dosage forms. All details and updates regarding the proposal will be available exclusively on sam.gov, with no paper copies distributed. Interested parties are encouraged to direct questions to the designated contracting officer, Chris Carthron.
36E79725R0008.docx
Jan 16, 2025, 10:06 PM UTC
The document outlines a Request for Proposal (RFP) from the Department of Veterans Affairs (VA) for pharmaceutical suppliers. The purpose is to establish a national contract for the provision of specific drug products, namely Carbidopa/Levodopa tablets, through its Pharmaceutical Prime Vendor (PPV) program. The RFP stipulates requirements for potential contractors, including pricing structures for the base year and four option years, product registration details, specific drug codes (NDCs), and compliance with the Drug Supply Chain Security Act (DSCSA). Additionally, the document emphasizes that contractors must have an acceptable Good Manufacturing Practices (cGMP) status and maintain manufacturer consistency throughout the contract period. Key details include the necessity for a Letter of Commitment from manufacturers or distributors, requirements for invoicing, quarterly sales reporting, and documenting contract compliance. The implementation period and delivery expectations are clearly defined, along with procedures for handling recalls and nonconformance issues. By outlining these parameters, the RFP reflects the VA’s commitment to ensuring a reliable drug supply at negotiated prices for veteran and military healthcare systems nationwide.
Lifecycle
Title
Type
6505--Carbidopa/Levodopa SA Tablet
Currently viewing
Solicitation
6505--Carbidopa/Levodopa SA Tablet
Presolicitation
Similar Opportunities
6505--Topiramate Tablets (VA-25-00047941)
Buyer not available
The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Topiramate Tablets, designated as Solicitation 36E79725R0031. This procurement aims to secure an uninterrupted supply of various forms of Topiramate for the VA, Department of Defense (DOD), Bureau of Prisons (BOP), and Indian Health Service (IHS), highlighting the importance of ensuring continuous access to essential pharmaceuticals across federal health services. The contract will span one year with four additional pre-priced option years, and interested vendors must submit their proposals electronically by April 29, 2025, while providing the exact name of the drug along with a unique National Drug Code (NDC). For further inquiries, vendors can contact Contract Specialist Billy Fong at billy.fong@va.gov or by phone at 708-786-4992.
6505--Aprepitant Capsules
Buyer not available
The Department of Veterans Affairs is soliciting proposals for the supply of Aprepitant capsules, a pharmaceutical product essential for various government health facilities, including those under the Department of Defense and Indian Health Service. Offerors are required to provide pricing for multiple line items covering a base year and four option years, adhering to specific conditions such as a 0.5% Cost Recovery Fee and compliance with the Drug Supply Chain Security Act (DSCSA). The contract emphasizes the importance of maintaining current Good Manufacturing Practices (cGMP) and ensuring proper labeling and packaging of the products. Interested contractors should contact Contract Specialist Matthew S. Poulin at Matthew.Poulin@va.gov for further details and must submit their proposals in accordance with the outlined requirements.
6505--Loperamide Capsules (VA-25-00032225)
Buyer not available
The Department of Veterans Affairs (VA) is issuing a presolicitation notice for the procurement of Loperamide HCL 2MG Capsules under Request for Proposal (RFP) 36E79725R0025. This procurement aims to ensure a consistent supply of the medication not only for the VA but also for the Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC), with the intention to award one contract that spans one year with four optional one-year extensions. The estimated requirements include 18,690 bottles of 100 capsules and 47,289 bottles of 500 capsules annually, reflecting the importance of maintaining a steady supply of essential medications for healthcare facilities. Interested parties should note that the solicitation is expected to be electronically issued by April 17, 2025, with responses due by May 1, 2025; inquiries can be directed to Contracting Officer Andrew Cazares at Andrew.Cazares@va.gov or (719) 786-4990.
6505--Fludrocortisone Acetate Tablets (VA-25-00047932)
Buyer not available
The Department of Veterans Affairs is soliciting bids for the procurement of Fludrocortisone Acetate Tablets (0.1 MG) under the VA & DoD Pharmaceutical Prime Vendor Programs. Contractors are required to submit proposals that include pricing for a base year and four option years, adhering to specific guidelines such as a 0.5% Cost Recovery Fee and compliance with the Drug Supply Chain Security Act. This procurement is crucial for ensuring a consistent supply of essential pharmaceuticals to veterans, emphasizing the importance of Good Manufacturing Practices (cGMP) and the need for a unique National Drug Code (NDC) for each product offered. Interested contractors should contact Youlanda Duggar at youlanda.duggar@va.gov for further details and to ensure compliance with all submission requirements.
6505--760-25-1-050-0237 -Leavenworth CMOP OM PHARMACEUTICALS -(VA-25-00028391)
Buyer not available
The Department of Veterans Affairs (VA) is preparing to issue a request for proposal (RFP) for the procurement of fourteen specified pharmaceuticals to be delivered to the Leavenworth Consolidated Mail Outpatient Pharmacy (CMOP) facility in Kansas. This opportunity is exclusively set aside for small businesses under the product service code 6505, which pertains to drugs and biologicals, and requires interested vendors to submit a price schedule, a signed SF1449 cover page, valid state wholesale distributor licenses, and a Buy American Act certificate. The procurement is crucial for ensuring that veterans receive timely access to necessary pharmaceuticals, with the estimated RFP issue date set for March 6, 2025, and a response deadline of March 17, 2025. Interested parties should direct their submissions and inquiries to Contracting Officer Kelley Cunningham at kelley.cunningham@va.gov or by phone at 913-684-0140.
6505--Hydroxychloroquine SO4 Tablets
Buyer not available
The Department of Veterans Affairs is soliciting offers for the procurement of Hydroxychloroquine SO4 Tablets, specifically 200mg tablets, through its National Acquisition Center. The solicitation outlines the requirements for supply contracts, including compliance with Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), as well as the need for a unique National Drug Code (NDC) for each product. This procurement is crucial for ensuring a consistent supply of pharmaceuticals to government healthcare facilities, thereby maintaining availability and pricing stability. Interested contractors should note that the deadline for submitting offers has been extended to April 8, 2025, at 2:30 PM CDT, and can reach out to Contract Specialist Christopher Carthron at Christopher.Carthron@va.gov for further inquiries.
6505--Perphenazine Tablets (VA-25-00037353)
Buyer not available
The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Perphenazine Tablets under solicitation number 36E79725R0030. This unrestricted procurement aims to ensure a continuous supply of Perphenazine Tablets for the VA, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Centers, with a contract period of one year and the potential for four additional one-year option periods. The estimated annual requirements include various dosages of Perphenazine Tablets, with specific quantities outlined for each dosage form. Interested offerors must submit their proposals electronically by April 24, 2025, following the anticipated release of the solicitation on April 10, 2025. For inquiries, contact Anthony Di Crescenzo at anthony.dicrescenzo@va.gov or by phone at 708-786-4984.
760-25-1-050-0154 -Leavenworth CMOP THYROID TABLETS -(VA-25-00022614)
Buyer not available
The Department of Veterans Affairs is soliciting proposals for the procurement of Armour Thyroid tablets for the Leavenworth Consolidated Mail Outpatient Pharmacy (CMOP) under solicitation number 36C77025Q0079. This Request for Quotation (RFQ) emphasizes the need for specific brand-name pharmaceuticals, with a focus on compliance with federal regulations, including the Drug Supply Chain Security Act and the Buy American Act. The procurement process aims to ensure a reliable supply of essential medications for veterans, with a firm-fixed-price contract expected to be awarded based on fair market evaluations. Interested vendors must submit their quotes by December 27, 2024, at 4:00 PM CST, and can direct inquiries to Jennifer L. Knight at jennifer.knight@va.gov or by phone at 913-684-0162.
Seeking Domestic Pharmaceuticals
Buyer not available
The Department of Veterans Affairs is seeking qualified domestic manufacturers to provide seven specific pharmaceuticals for its Consolidated Mail Outpatient Pharmacy (CMOP) program. The procurement aims to identify sources capable of supplying medications such as Trazodone, Sertraline, and Hydroxychloroquine, which are essential for the healthcare needs of veterans across multiple facilities in the United States. Interested companies are encouraged to submit capability statements detailing their products, distribution capabilities, and compliance with federal regulations, as responses will inform future contracting strategies. For further inquiries, interested parties may contact Josie M Linaweaver at josie.linaweaver@va.gov or by phone at 913-684-0155.
6505--770_Pharmaceuticals_VA CMOP National Office_36C77025Q0196 770-25-3-801-0371 -National CMOP A1222 ACAMPROSATE TAB
Buyer not available
The Department of Veterans Affairs is seeking vendors to provide Acamprosate Calcium 333mg EC tablets under solicitation number 36C77025Q0196 for delivery to multiple Consolidated Mail Outpatient Pharmacy (CMOP) facilities. The procurement includes specific quantities of the pharmaceuticals, with a total of six different shipment requirements outlined, emphasizing compliance with the Drug Supply Chain Security Act (DSCSA) and adherence to federal regulations regarding pharmaceutical distribution. This opportunity is critical for ensuring the availability of essential medications for veterans' healthcare, reflecting the VA's commitment to quality and regulatory compliance in its supply chain. Interested vendors must submit their quotes, including a signed Standard Form 1449, a detailed price schedule in Excel format, and a state wholesale distributor license by April 9, 2025, with the estimated award date set for April 14, 2025. For further inquiries, vendors can contact Michael W McAlhaney at Michael.McAlhaney@va.gov or by phone at (913) 684-0134.